Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications.
The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
Company Details
- Employees
- 29
- Founded
- -
- Address
- London, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://pulmocide.com/
- Keywords
- Severe respiratory diseases, Inhaled therapeutics, Pulmonary aspergillosis, Pharmaceuticals, Acute and chronic lung infections, Pulmonary.
- HQ
- London
Pulmocide Questions
Pulmocide's website is https://pulmocide.com/
Pulmocide's LinkedIn profile is https://www.linkedin.com/company/pulmocide
Pulmocide has
29 employees.
View email and phone details for 29
employees at Pulmocide.
Pulmocide's industry is
Biotechnology Research
Pulmocide's top competitors are
Artios,
Cellcentric,
Quell Therapeutics,
Aviadobio,
Touchlight,
Autolus Therapeutics,
Ellipses Pharma,
Bit.bio,
Cell And Gene Therapy Catapult,
Evox Therapeutics Ltd.
Pulmocide's categories are Biotechnology Research
Pulmocide's founding year is 2013
